Back to Search Start Over

Allogeneic stem-cell transplantation for lymphoproliferative disorders using BEAM-CAMPATH (+/- fludarabine) conditioning combined with post-transplant donor-lymphocyte infusion.

Authors :
Lush RJ
Haynes AP
Byrne J
Cull GM
Carter GI
Pagliuca A
Parker JE
Mufti G
Mahendra P
Craddock CF
Lui Yin JA
Garg M
Prentice HG
Potter MN
Russell NH
Source :
Cytotherapy [Cytotherapy] 2001; Vol. 3 (3), pp. 203-10.
Publication Year :
2001

Abstract

Background: We report our updated experience of allogeneic transplantation in lympho-proliferative disorders using a reduced-intensity conditioning regimen combining BEAM (plus fludarabine in three cases) with pre-transplant CAMPATH. Post-transplant donor lymphocytes have been infused for persisting disease or relapse, and both chimerism and minimal residual disease have been monitored utilizing molecular techniques.<br />Methods: Thirty patients with median age 47.6 years underwent allogeneic transplantation for relapsed or high-risk lymphoproliferative disease using HLA-identical (sibling n = 25, unrelated n = 2) or one antigen mismatched sibling donors (n = 3). Twenty-one had NHL, three had HD and six had CLL/PLL. Stem-cell source was PBSC (n = 24), BM (n = 5) or both (n = 1) with a median CD34 dose of 4.5 x 10(6)/kg. GvHD prophylaxis was with CYA and MTX.<br />Results: Engraftment was prompt in the majority of patients, with a median of 15 days to both ANC > 0.5 and platelets > 20. There have been three transplant-related deaths secondary to viral pneumonitis or bacterial pneumonia. Seven patients developed Grade I-II acute GvHD post-transplant. Of 28 evaluable patients, 18 achieved a CR at assessment 2-3 months post-transplant and a further patient converted from PR to CR following DLI, to give an overall CR rate of 68%. Three patients had early progressive disease and six have relapsed from CR or progressed from PR (two of whom have achieved CR following DLI therapy). Overall survival is 67% and event-free survival 48% at 3 years. With a median follow-up of 1.3 years 57% of patients are currently alive and lymphoma-free. A molecular remission has been achieved in nine of 12 informative patients.<br />Discussion: These encouraging results show that this reduced-intensity conditioning regimen is effective, with a low-toxicity profile compared with conventional TBI-based conditioning, and certainly merits further evaluation in this setting.

Subjects

Subjects :
Adolescent
Adult
Alemtuzumab
Antibodies, Monoclonal adverse effects
Antibodies, Monoclonal toxicity
Antibodies, Monoclonal, Humanized
Antibodies, Neoplasm adverse effects
Antibodies, Neoplasm toxicity
Antineoplastic Combined Chemotherapy Protocols adverse effects
Antineoplastic Combined Chemotherapy Protocols toxicity
Blood Donors
Carmustine adverse effects
Carmustine toxicity
Cytarabine adverse effects
Cytarabine toxicity
Disease Progression
Etoposide adverse effects
Etoposide toxicity
Female
Graft Survival drug effects
Graft Survival immunology
Graft vs Host Disease drug therapy
Graft vs Host Disease immunology
Graft vs Host Disease prevention & control
Humans
Immunosuppression Therapy trends
Lymphocyte Transfusion methods
Lymphocyte Transfusion trends
Lymphoproliferative Disorders immunology
Lymphoproliferative Disorders physiopathology
Male
Melphalan adverse effects
Melphalan toxicity
Middle Aged
Monitoring, Physiologic
Secondary Prevention
Stem Cell Transplantation adverse effects
Survival Rate
Transplantation Chimera immunology
Transplantation Conditioning trends
Transplantation, Homologous adverse effects
Treatment Outcome
Antibodies, Monoclonal therapeutic use
Antibodies, Neoplasm therapeutic use
Antineoplastic Combined Chemotherapy Protocols therapeutic use
Carmustine therapeutic use
Cytarabine therapeutic use
Etoposide therapeutic use
Immunosuppression Therapy methods
Lymphoproliferative Disorders therapy
Melphalan therapeutic use
Stem Cell Transplantation methods
Transplantation Conditioning methods
Transplantation, Homologous methods

Details

Language :
English
ISSN :
1465-3249
Volume :
3
Issue :
3
Database :
MEDLINE
Journal :
Cytotherapy
Publication Type :
Academic Journal
Accession number :
12171727
Full Text :
https://doi.org/10.1080/146532401753174034